This week PharmaTell had Eyes On: Heartburn – the kind caused by the upcoming Zantac litigation & resulting market jitters.

This week we had Eyes On Amazon & One Medical – as did many of you, I am sure. We saw the news and, of course, had a variety of thoughts...

We are excited to announce PharmaTech Outlook selected us as one of the Top 10 Pharma Marketing Services Companies in Europe – 2022!

The PharmaTell Team has had Eyes On — The Pharma CI Europe Conference, US FDA Regulatory Updates. Plus 2H22 Clinical Data Readouts.

As with most of you I'm sure - this week the PharmaTell Team had Eyes on ASCO + positive data for postpartum depression patients.

PharmaTell had Eyes on the US Baby Formula Shortage this week. I was curious as to how this happened

This was a busy week for Healthcare with 1Q22 Results. The PharmaTell Team had eyes on some of the US FDA decisions + Roche's SKYSCRAPER-01

The PharmaTell Team has been busy curating Quarterly Results reports & upcoming conference planners + keeping up with Biogen next steps.

This week the team has been enjoying the spring holidays and keeping their eyes on some of the recent news from AACR and learning a bit more

We are excited to share the latest upgrades to PharmaTell Studio making it even easier for you to keep your eyes on you & your competition.

This week, the team has been looking at congress planners, earnings call transcripts, and the US FDA.

This week, the team had Eyes on the new draft guidance from the US FDA on Gene Therapy Products Incorporating Genome Editing.

Today we’ll share some of the types of reports available that can help you keep your Eyes on Pharma Sectors.

We found several different types of intel so we thought we would share some with you – and tips on how to find it.

Check out the latest on some of the Opioid Litigation, SPACS, and yes two Top 10 Lists!

The Eyes on Pharma team was caught up in reviewing global R&D trends and following the updates from ASCO-GU ...